Linarigenin could arrest the cell cycle of human lung cancer A549 cells and human liver cancer HepG2 cells by increasing the expression of CDK endogenous inhibitors, p53 and p21 genes [128]. The gene discussed is TP53; the disease is lung carcinoma.